Project Grant HT94252410610
Award Date
6/1/24
Completion Date
5/31/26
Dollars Obligated
$648K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
The University of Texas MD Anderson Cancer Center received a $567,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant, awarded on September 1, 2024, will fund research targeting myeloid mimicry in renal medullary carcinoma, with a completion date of August 31, 2027. Through this federal grant, MD Anderson Cancer Center will conduct innovative scientific studies, ranging from basic laboratory research to advanced...
The University of Texas MD Anderson Cancer Center, a component of the University of Texas System, received a $486,000 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The 3-year grant, with a start date of September 30, 2023, supports research targeting the PRMT5 protein in melanoma with MTAP gene loss. The funding will enable preclinical studies, including evaluating novel treatments, to advance the understanding and...
The University of Texas MD Anderson Cancer Center received a $647,998 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The award will fund research to develop image-guided, bidirectional EphB4 agonist-based therapy for ovarian cancer over a 4-year period from September 1, 2023 to August 31, 2027. MD Anderson, a comprehensive cancer treatment and research center, has extensive experience conducting basic,...
This $3,945,543 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports cancer research and care initiatives at the University of Texas MD Anderson Cancer Center (MD Anderson). The award will fund a 4-year clinical research extension project to advance progress, precision, and equity in breast cancer care. MD Anderson, a leading comprehensive cancer center, will utilize the funding to conduct research activities that...
The U.S. Department of Defense's Defense Health Agency has awarded a $1,882,607.00 Project Grant to The University of Texas MD Anderson Cancer Center (MD Anderson) under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant, titled "LEVERAGING PROSTATE CANCERS' UNIQUE LIPID METABOLISM TO INDUCE THERAPEUTIC FERROPTOSIS," aims to conduct advanced biomedical research focused on transforming healthcare for military service members and the general...
The U.S. Defense Health Agency has awarded a $7,001,734 Project Grant to The University of Texas MD Anderson Cancer Center to advance the understanding of metastatic breast cancer through the development of a comprehensive research platform. The grant, which runs from August 15, 2024 to August 14, 2028, is funded under the Military Medical Research and Development (CFDA 12.420) program. The project aims to drive innovative cancer research and explore new approaches to prevention, diagnosis,...
The University of Texas MD Anderson Cancer Center will receive $729,000 through a Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from August 2021 through August 2025 to translate novel discoveries in gastric adenocarcinoma biology into therapeutic advances. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to...
The University of Texas MD Anderson Cancer Center received a $1,619,997 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research on targeting ferroptosis and mitochondrial pathways in acute myeloid leukemia. The 3-year award, which commenced on September 1, 2023, will support preclinical studies, clinical trials, and other research activities at the cancer center's facilities in Houston, Texas. As a component...
This $1,619,723 federal Project Grant award from the Department of Defense's Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides funding to The University of Texas MD Anderson Cancer Center to conduct research targeting novel mediators of breast cancer brain metastasis. The award period runs from April 1, 2024 to March 31, 2027, with the goal of developing new treatments, improving patient care, and advancing scientific understanding in this...
This Project Grant award from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), provides $1,444,922.00 to the University of Texas MD Anderson Cancer Center (MD Anderson) to conduct research on a novel epigenetic determinant in metastatic prostate cancer. The award period is from September 15, 2024 to September 14, 2027. MD Anderson, a comprehensive cancer research and treatment center, will utilize this funding to carry out basic,...